RxDoctor Payments Data

Brett Fortune, MD

Hepatology · Miami, FLNPI 1720121585

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 31.5% of the total. 2025 is the largest year on record at $56,594, 2.1 times the $27,538 reported in 2019.

$147,494in general payments, 2019–2025

Across 152 payments — averaging $970.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$46K
  • Novo Nordisk$35K
  • Madrigal Pharmaceuticals$20K
  • BD$9K
  • Bard Peripheral Vascular, Inc.$9K
  • Dova Pharmaceuticals$7K
  • plus $21K from 11 others
$219,690in research payments, 2019–2025

Across 44 payments — averaging $4992.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$96K
  • AstraZeneca$92K
  • Grifols Therapeutics LLC$14K
  • Dova Pharmaceuticals$13K
  • Mallinckrodt Enterprises LLC$5K

What the payments were for

  • Consulting fees$57,72339%
  • Speaking & faculty fees$70,37448%
  • Travel & lodging$12,1718%
  • Food & beverage$7,2265%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$24,913
Medicare patients
90
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tenofovir Disoproxil Fumarate22$5,314
Ursodiol35$2,419
Spironolactone15$173
Carvedilol26$74

Paid to pharmacies, not to this prescriber.

Other hepatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →